Volta AI software in real-world AF ablation
Official title: Real-World Experience of Volta Medical AI-software During AF Ablation Using Next-generation Mapping and Ablation Technologies
Run by Volta Medical · NCT07621055 · Data updated 2026-11-12
A real-world observational study will test the latest Volta AF-Xplorer II AI software during atrial fibrillation ablation to see how safe and effective it is over 24 months.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Volta Medical Industry-sponsored |
| Locations | 3 sites (Marseille and 2 other locations) |
| Status | Recruiting |
| Started | June 16, 2026 |
| Main results expected | June 2030 |
| Study ends | June 2030 |
| Registry record updated | June 22, 2026 |
| Trial ID | NCT07621055 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18+ with paroxysmal or persistent AF or related tachycardias eligible for catheter ablation and where Volta AF-Xplorer II is considered for use, in France.
✕Probably not a fit
Patients for whom the operator does not use Volta AF-Xplorer II or who have contraindications to the ablation approach may not experience any benefit from the AI software.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This PMCF study observes acute and long-term safety and performance of Volta AF-Xplorer II during AF ablation in routine clinical practice. It uses next-generation mapping and ablation tools, with the ablation approach chosen by the operator. Participants are followed through standard care visits at 3, 6, 9 and 24 months, collecting adverse events, arrhythmia recurrences, heart failure symptoms, AF-related symptoms, and a general health quality-of-life measure. The study records outcomes from enrollment to 24 months post-ablation, without imposing new workflows.
Why it matters
Potential benefit: If successful, patients may experience improved ablation guidance and potentially better safety and effectiveness through the AI software.
How similar studies have gone: Previous studies using similar AI-guided mapping tools have shown promise, but this specific real-world PMCF with Volta AF-Xplorer II is still exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patient aged 18 years or older. 2. Patient candidate for catheter ablation to treat paroxysmal or persistent atrial fibrillation, atrial tachycardia, de novo or after one or several previous ablation procedures, and for which the investigator considers using Volta AF-Xplorer II. 3. Patient able and willing to provide written informed consent to participate in the study. 4. Only for France: Patient affiliated to the French social security system. Exclusion Criteria: 1. Contraindication to AF/AT catheter ablation using RF and/or PFA. 2. Patient who is or could potentially be pregnant. 3. Person deprived of liberty or under guardianship. 4. Person unable to undergo a medical monitoring for geographical, social or psychological reasons. 5. Patient's refusal to participate in the study. 6. Enrollment in a premarket clinical study evaluating device, drug or biologic product.
Where it's running
-
Hôpital Saint-Joseph Marseille
Marseille, France Recruiting -
Centre Cardiologique du Nord
Saint-Denis, France Not yet recruiting -
Clinique Rhéna
Strasbourg, France Not yet recruiting
Study contacts
- Principal investigator: Clément BARS, MD — Hôpital Saint Joseph Marseille
- Study coordinator: Paola MILPIED
- Email: paola.milpied@volta-medical.com
- Phone: +33768025499
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AV node ablation with left bundle branch area pacing versus right ventricular pacing for atrial fibrillation with preserved heart function
This test checks whether left bundle branch area (LBBA) pacing instead of right ventricular (RV) pacing after AV node ablation better preserves heart function in adults with symptomatic atrial fibrillation and normal ejection fraction.
-
Using the VERAFEYE imaging and navigation system to guide catheter ablation for atrial arrhythmias
This study will try the VERAFEYE imaging and guidance system during catheter ablation in adults with atrial flutter or atrial fibrillation to see if it integrates well with standard procedures.
-
Anatomical navigation to guide catheter ablation for atrial fibrillation and flutter
This trial will test whether the VERAFEYE Anatomical Guidance System helps doctors guide catheter ablation in adults with atrial fibrillation or atrial flutter.
-
Heart assessment to check repeat-stroke risk in people with atrial fibrillation
This project will test whether detailed heart examinations can find which people with atrial fibrillation who just had an ischemic stroke are at high risk of having another stroke.
-
Sensor-guided exercise program for people with atrial fibrillation
This program will test whether a Fitbit-based, personalized exercise plan can reduce symptoms and episode burden in people with paroxysmal atrial fibrillation.
-
Understanding brain and heart injuries after bleeding in the brain
This study looks at how bleeding in the brain affects both the brain and the heart in adults to better understand the connection between these injuries.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.